Piper Sandler analyst Joseph Catanzaro downgraded ImmunoGen (IMGN) to Neutral from Overweight with a price target of $31, up from $24. Last week, AbbVie (ABBV) announced that it will acquire ImmunoGen for $31.26/share, with deal closure expected in mid-2024. This allows AbbVie to take another step into the ADC landscape, where it has spent considerable efforts, but this time a deal that brings an approved product and validated platform, the firm says. For ImmunoGen, Piper thinks the deal comes at a great price and at the ideal time as it heads into 2024 with questions around when the Elahere launch might hit a ceiling given its robust uptake. Overall, this represents yet another ADC deal with large pharma now the predominant player in this space, says the firm.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMGN:
- ImmunoGen downgraded to Equal Weight from Overweight at Barclays
- ImmunoGen downgraded to Hold from Buy at Jefferies
- AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker
- ImmunoGen downgraded to Neutral from Buy at Guggenheim
- ImmunoGen downgraded to Market Perform from Outperform at BMO Capital
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue